Kidney-dialysis titan DaVita defends patient care, business practices
By Christopher N. Osher, Jennifer Brown and Michael Booth
The Denver Post
Posted: 05/07/2011 11:24:05 PM MDT
Updated: 05/08/2011 11:39:18 AM MDT
A dialysis treatment machine at DaVita Lowry Dialysis Center in Denver, Colorado. ( Joe Amon, The Denver Post)
DaVita, a Fortune 500 company, is building a $101 million, 14-story corporate headquarters in Lower Downtown. Over the past decade, the kidney dialysis company has amassed 1,612 dialysis centers. (Andy Cross, The Denver Post)
The relocation to Denver last year of kidney-dialysis titan DaVita was good news to a local economy battered by the recession.
But as the Fortune 500 company's $101 million, 14-story corporate headquarters rises in Lower Downtown, it continues to battle questions about its business practices.
Chief among the accusations, raised in federal investigations and lawsuits, is that DaVita overused a lucrative anemia drug called Epogen in order to receive higher government reimbursements.
The Food and Drug Administration has warned since 2007 that the drug, routinely used to help anemic patients on dialysis, also can increase the risk of death when used at certain levels.
DaVita officials energetically defend their company and say they never put patients at risk.
They say that doctors ultimately decide how much Epogen to use and that the company's protocols on the drug's use are aimed solely at keeping patients healthy. They said a corporate recommendation in December to use less of the drug was tied to evolving science and not to a reduction in government reimbursements that took effect three weeks later.
"DaVita has done, in my view, a spectacular job of improving